Sheeba K. Thomas

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

M Wang, Nathan Fowler, Nicolaus A. Wagner‐Bartak et al. · Leukemia · 2013 · 204 citations

Medicine, Oncology, Pharmacotherapy +16

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones et al. · Blood · 2012 · 172 citations · Full text

Medicine, Oncology, Pharmacology +17

Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma

Uday Popat, Rima M. Saliba, Rupinderjit S Thandi et al. · Biology of Blood and Marrow Transplantation · 2009 · 168 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study

Roger G. Owen, Helen O. McCarthy, Simon Rule et al. · The Lancet Haematology · 2019 · 164 citations · Full text

Medicine, Hematology, Pharmacology +4

Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study

Suzanne Trudel, Adam D. Cohen, Amrita Krishnan et al. · Blood · 2021 · 161 citations

Medicine, Pharmacology, Pharmacotherapy +9